Ditemukan 1397 dokumen dengan kata kunci 8888 |
Simpan CSV  |
Bevacizumab plus chemotherapy continued beyond first progression in patients withmetastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings†
|
|
Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group
|
|
A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial
|
|
FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study
|
|
Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study
|
|
Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer
|
|
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study
|
|
Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer
|
|
Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer†
|
|
Racial Disparity in Consultation, Treatment, and the Impact on Survival in Metastatic Colorectal Cancer
|
No. Panggil: JNCI Journal of the National Cancer Institute; Volume 105, No.23, 4 December 2013: p.1814-1820 |
|
Koleksi: Artikel Internasional - Oxford ::
Cari yang mirip ::
Tambahkan ke Favorit ::
|
|